Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
ETFs with TTPH as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0.42%||Wilshire Micro-Cap ETF (based on the Wilshire US Micro-Cap Ind (WMCR)||-1.57 (-5.54%)|
Company Description (as filed with the SEC)
We are a clinical-stage biopharmaceutical company using our proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. We are developing our lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a broad-spectrum intravenous, or IV, and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. We are conducting a global Phase 3 clinical program for eravacycline called IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline), consisting of two Phase 3 clinical trials. IGNITE 1 is a Phase 3 clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections, or cIAI, for which we announced top-line data in December 2014. ... More ...
Where does TTPH fit in the risk graph?
|Annual EPS Est:||$-2.49|
|Quarterly EPS Est:||-0.49|